Transferability of European-derived Alzheimer's Disease Polygenic Risk Scores across Multi-Ancestry Populations.

Aude Nicolas[1,2,*,#], Richard Sherva[3,4,*], Benjamin Grenier-Boley[1,*], Yoontae Kim[5,*], Masataka Kikuchi[6], Jigyasha Timsina[7,8], Itziar de Rojas[9,10], María Carolina Dalmasso[11,12], Xiaopu Zhou[13,14,15], Yann Le Guen[16,17], Carlos E Arboleda-Bustos[18], Maria Aparecida Camargos Bicalho[19,20,21], Maëlenn Guerchet[22], Sven van der Lee[23,24], Monica Goss[25], Atahualpa Castillo[26], Céline Bellenguez[1], Fahri Küçükali[27,28], Claudia Satizabal Barrera[25,29,30], Bernard Fongang[25,31,32], Qiong yang[29,30], Oliver Peters[33,34], Anja Schneider[35,36], Martin Dichgans[37,38,39], Dan Rujescu[40], Norbert Scherbaum[41], Jürgen Deckert[42], Steffi Riedel-Heller[43], Lucrezia Hausner[44], Laura Molina Porcel[45,46], Emrah Düzel[47,48], Timo Grimmer[49], Jens Wiltfang[50,51,52], Stefanie Heilmann-Heimbach[53], Susanne Moebus[54], Thomas Tegos[55], Nikolaos Scarmeas[56,57], Oriol Dols-Icardo[58,10], Fermin Moreno[59,10,60], Jordi Pérez-Tur[61,10], María J. Bullido[62,10,63,64], Pau Pastor[65,66], Raquel Sánchez-Valle[67], Victoria Álvarez[68,69], Han Cao[13], Nancy Y. Ip[13,14,15], Amy K. Y. Fu[13,14,15], Fanny C. F. Ip[14,15], Natividad Olivar[70], Carolina Muchnik[70], Carolina Cuesta[71], Lorenzo Campanelli[72], Patricia Solis[73], Daniel Gustavo Politis[71], Silvia Kochen[73], Luis Ignacio Brusco[70], Mercè Boada[74,10], Pablo García-González[74], Raquel Puerta[74], Pablo Mir[75,10], Luis M Real[76,77,10], Gerard Piñol-Ripoll[78,79], Jose María García-Alberca[80,10], Jose Luís Royo[81], Eloy Rodriguez-Rodriguez[82,10], Hilkka Soininen[83], Sami Heikkinen[84], Alexandre de Mendonça[85], Shima Mehrabian[86], Latchezar Traykov[87], Jakub Hort[88,89], Martin Vyhnalek[88,89], Katrine Laura Rasmussen[90,91], Jesper Qvist Thomassen[90], Yolande A.L. Pijnenburg[23], Henne Holstege[23,92], John van Swieten[93], Harro Seelaar[93], Jurgen A.H.R. Claassen[94,95], Willemijn J. Jansen[96], Inez Ramakers[97], Frans Verhey[97], Aad van der Lugt[98], Philip Scheltens[23], Jenny Ortega-Rojas[18], Ana Gabriela Concha Mera[18], Maria F. Mahecha[18], Rodrogo Pardo[18], Gonzalo Arboleda[18], Shahram Bahrami[99,100], Vera Fominykh[99,100], Geir Selbæk[101,102], Caroline Graff[103], Goran Papenberg[104], Vilmantas Giedraitis[105], Anne Boland[106], Jean-François Deleuze[106], Luiz Armando de Marco[107,20], Edgar Nunes de Moraes[19,21], Bernardo de Mattos Viana[108,20,109], Marco Túlio Gualberto Cintra[19,21], Teresa Juárez-Cedillo[110], Anthony Grsiwold[111], Tatiana Forund[112], Jonathan Haines[113], Lindsay Farrer[114,115,116,117,118], Anita DeStefano[119], Ellen Wijsman[120,121,122], Richard Mayeux[123,124], Margaret Pericak-Vance[111,125], Brian Kunkle[111], Alison Goate[126], Gerard D. Schellenberg[127], Badri Vardarajan[123,124,128], Li-San Wang[127], Yuk Yee Leung[127], Clifton Dalgard[129], Gael Nicolas[130], David Wallon[130], Carole Dufouil[131,132], Florence Pasquier[133], Olivier Hanon[134], Stéphanie Debette[135,136], Edna Grünblatt[137,138,139], Julius Popp[140,141,142], Bárbara Angel[143,144,145], Sergio Golger[146,147], Maria Victoria Chacon[146], Rafael Aranguiz[146,148,149], Paulina Orellana[150,151], Andrea Slachevsky[150,152], Christian Gonzalez-Billault[152], Cecilia Albala[143,144], Patricio Fuentes[153,154], Perminder Sachdev[155], Karen Mather[155], Richard L. Hauger[156,157], Victoria Merritt[158,159,160], Matthew Panizzon[159,161,160], Rui Zhang[3], Michael Gaziano[162,163], Roberta Ghidoni[164], Daniela Galimberti[165,166], Beatrice Arosio[167], Patrizia Mecocci[168,169], Vincenzo Solfrizzi[170], Lucilla Parnetti[171], Alessio Squassina[172], Lucio Tremolizzo[173], Barbara Borroni[174,175], Benedetta Nacmias[176,177], Paolo Caffarra[178], Davide Seripa[179], Innocenzo Rainero[180], Antonio Daniele[181,182], Fabrizio Piras[183], EADB, Hampton L, Leonard[184,185], Jennifer S. Yokoyama[186,187,188,189], Mike A, Nalls[184,190,185], Akinori Miyashita[191], Norikazu Hara[191], Kouichi Ozaki[192], Shumpei Niida[192], Julie Williams[193,26], Carlo Masullo[194], Philippe Amouyel[1], Pierre-Marie Preux[22], Pascal Mbelesso[22,195], Bébène Bandzouzi[196], Andy Saykin[197,112], Frank Jessen[198,35,199], Patrick Kehoe[200], Cornelia Van Duijn[201,202], Nesrine Ben Salem[203], Ruth Frikke-Schmidt[90,91], Lofti Cherni[203,204], Michael D. Greicius[16], Magda Tsolaki[55,204], Pascual Sánchez-Juan[205,10], Marco Aurélio Romano Silva[108,20], Tenielle Porter[206,207,208], Simon M Laws[206,207,208], Kristel Sleegers[27,28], Martin Ingelsson[209,210,211], Jean-François Dartigues[212], Sudha Seshadri[25,29,30], Giacomina Rossi[213], Laura Morelli[72], Mikko Hiltunen[84], Rebecca Sims[26], Wiesje van der Flier[23], Ole Andreassen[99,100], Humberto Arboleda[18], Carlos Cruchaga[7,8], Valentina Escott-Price[214,193], Agustín Ruiz[10,25,215], Kun Ho Lee[5,216,217,218], Takeshi Ikeuchi[191], Alfredo Ramirez[219,220,221,222,223], Jungsoo Gim[5,216,217,224,**], Mark Logue[225,226,227,228,**], Jean-Charles Lambert[1,**]

* co-first, **co-last

[#]corresponding authors

Aude.nicolas.deydier@gmail.com and jean-charles.lambert@pasteur-lille.fr

[1]Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France
[2]Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, CNRS, APHP, Hôpital de La Pitié Salpêtrière, Inserm Paris, France
[3]National Center for PTSD, Behavioral Sciences Division, VA Boston Healthcare System, Boston, MA, USA
[4]Biomedical genetics/Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
[5]BK FOUR Department of Integrative Biological Sciences, Chosun University, Gwangju, Republic of Korea
[6]University of Tokyo, Graduate School of Frontier Science, Japan
[7]Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA
[8]NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO 63110, USA
[9]Research Center and Memory Clinic, ACE Alzheimer Center Barcelona. Universitat Internacional de Catalunya, Spain
[10]CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain
[11]Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
[12]Studies in Neuroscience adn Complex Systems Unit (ENyS) CONICET-HEC-UNAJ, Argentina
[13]Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong China
[14]Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
[15]Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development, HKUST Shenzhen Research Institute, Shenzhen–Hong Kong Institute of Brain Science, Shenzhen, Guangdong 518057 China
[16]Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA
[17]Institut du Cerveau - Paris Brain Institute - ICM, Paris, France
[18]Neuroscience and Cell Death Research Groups, Medical School and Genetic Institute, Universidad Nacional de Colombia, Bogota, Colombia
[19]Department of Clinical Medicine, Federal University of Minas Gerais (UFMG) Belo Horizonte, Minas Geraes, Brazil
[20]National Institute of Science and Technology (INCT) Neurotec R, Federal University of Minas Geraes, Belo Horizonte, Minas Geraes, Brazil
[21]Geriatrics Service of the University Hospital, Federal University of Minas Gerais, Belo Horizonte, Minas Geraes, Brazil
[22]Inserm U1094, IRD UMR270, Univ. Limoges, CHU Limoges, EpiMaCT - Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, Limoges, France
[23]Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
[24]Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije University, Amsterdam, The Netherlands.
[25]Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA
[26]Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Wales, UK
[27]Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
[28]Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
[29]Boston University and the NHLBI's Framingham Heart Study, Boston, MA, USA
[30]Department of Neurology, Boston University School of Medicine, Boston, MA, USA
[31]Department of Biochemistry and Structural Biology, University of Texas Health Science Center, San Antonio, TX, USA
[32]Department of Population Health Sciences, University of Texas Health Science Center, San Antonio, TX, USA
[33]German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
[34]Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Psychiatry and Psychotherapy, Hindenburgdamm 30, 12203 Berlin, Germany
[35]German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
[36]Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Venusberg-Campus 1, Bonn, Germany
[37]Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
[38]German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
[39]Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
[40]Department of Psychiatry and Comprehensive Center of Neuroscience and Mental Health, Medical University of Vienna, Vienna, Austria
[41]Department of Psychiatry and Psychotherapy, LVR-Klinikum Essen, University of Duisburg-Essen, Germany Medical Faculty, Germany
[42]Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany
[43]Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, 04103 Leipzig, Germany.
[44]Department of Geriatric Psychiatry, Central Institute for Mental Health Mannheim, Faculty Mannheim, University of Heidelberg, Germany
[45]Neurological Tissue Bank - Biobanc- Hospital Clinic -FRCB - IDIBAPS, Barcelona, Spain
[46]Alzheimer's disease and other cognitive disorders Unit. Neurology Department, Hospital Clinic , Barcelona, Spain
[47]German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
[48]Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany
[49]Center for Cognitive Disorders, Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany
[50]Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany
[51]German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany
[52]Medical Science Department, iBiMED, Aveiro, Portugal
[53]Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany
[54]Institute for Urban Public Health, University Hospital Essen, University Duisburg-Essen, Germany
[55]1st Department of Neurology, Medical school, Aristotle University of Thessaloniki, Thessaloniki, Makedonia, Greece
[56]1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School, Greece
[57]Depatment of Neurology, Columbia University, New York, NY, USA
[58]Genetics of Neurodegenerative Diseases Unit IIB Sant Pau, Barcelona, Spain

[59]Department of Neurology. Hospital Universitario Donostia. San Sebastian, Spain
[60]Neurosciences Area. Instituto Biogipuzkoa. San Sebastian, Spain
[61]Unitat de Genètica Molecular, Institut de Biomedicina de València-CSIC, Valencia, Spain
[62]Centro de Biología Molecular Severo Ochoa (UAM-CSIC), Spain
[63]Instituto de Investigacion Sanitaria 'Hospital la Paz' (IdIPaz), Madrid, Spain
[64]Universidad Autónoma de Madrid, Spain
[65]Unit of Neurodegenerative diseases, Department of Neurology, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
[66]The Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain
[67]Alzheimer's disease and other cognitive disorders unit. Service of Neurology. Hospital Clínic of Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
[68]Laboratorio de Genética. Hospital Universitario Central de Asturias, Oviedo, Spain
[69]Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Spain
[70]Center of Neuropsychiatry and Behavior Neurology, School of Medicine, University of Buenos Aires, Argentina
[71]Hospital Interzonal General de Agudos-Eva Perón, Argentina
[72]Laboratory of Brain Aging and Neurodegeneration. Fundacion Instituto Leloir-IIBBA, Argentina
[73]Studies in Neuroscience and Complex Systems Unit-CONICET-HEC-UNAJ, Argentina
[74]Research Center and Memory clinic. ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Spain
[75]Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología. Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain
[76]Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen de Valme, Spain
[77]Depatamento de Bioquímica Médica, Biología Molecular e Inmunología. Facultad de Medicina. Universidad de Sevilla. Sevilla, Spain
[78]Unitat Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida, Lleida, Spain
[79]Institut de Recerca Biomedica de Lleida (IRBLLeida), Lleida, Spain
[80]Alzheimer Research Center & Memory Clinic, Andalusian Institute for Neuroscience, Málaga, Spain.
[81]Depatamento de Especialidades Quirúrgicas, Bioquímica e Inmunología. Facultad de Medicina. Universidad de Málaga. Málaga, Spain
[82]Neurology Service, Marqués de Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, Spain.
[83]Institute of Clinical Medicine - Neurology, University of Eastern Finland, Finland
[84]Institute of Biomedicine, University of Eastern Finland, Finland
[85]Faculty of Medicine, University of Lisbon, Portugal
[86]Clinic of Neurology, UH "Alexandrovska", Medical University - Sofia, Sofia, Bulgaria
[87]Department of Neurology, UH "Alexandrovska", Medical University, Sofia, Bulgaria
[88]Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic
[89]International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic
[90]Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
[91]Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
[92]Department of Clinical Genetics, VU University Medical Centre, Amsterdam, The Netherlands
[93]Department of Neurology, ErasmusMC, The Netherlands
[94]Department of Geriatrics, Radboud university medical center, Research Institute for Medical Innovation, The Netherlands
[95]Department of Cardiovascular Sciences, University of Leicester, UK
[96]Maastricht University, Department of Psychiatry & Neuropsychology, Alzheimer Center Limburg, Maastricht, The Netherlands
[97]Maastricht University, Department of Psychiatry & Neuropsychologie, Alzheimer Center Limburg, Maastricht, The Netherlands
[98]Department of Radiology&Nuclear medicine, ErasmusMC, The Netherlands
[99]NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
[100]Institute of Clinical Medicine, University of Oslo, Oslo, Norway
[101]Norwegian Centre for Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway
[102]Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.
[103]Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital-Solna, 171 64 Stockholm Sweden
[104]Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden
[105]Dept.of Public Health and Carins Sciences / Geriatrics, Uppsala University, Sweden
[106]Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), 91057, Evry, France
[107]Department of Surgery, Federal University of Minas Gerais (UFMG) Belo Horizonte, Minas Geraes, Brazil
[108]Department of Psychiatry, Federal University of Minas Gerais (UFMG) Belo Horizonte, Minas Geraes, Brazil
[109]Psychiatry Service of the University Hospital, Federal University of Minas Gerais, Belo Horizonte, Minas Geraes, Brazil
[110]Unidad de Investigación Médica en Epidemiología Clínica, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico .
[111]The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA
[112]Department of Medical and Molecular Genetics, Indiana University, Indianapolis, Indiana, USA
[113]Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA
[114]Department of Biostatistics, Boston University, Boston, Massachusetts, USA
[115]Department of Epidemiology, Boston University, Boston, Massachusetts, USA
[116]Department of Medicine (Biomedical Genetics), Boston University, Boston, Massachusetts, USA
[117]Department of Neurology, Boston University, Boston, Massachusetts, USA
[118]Department of Ophthalmology, Boston University, Boston, Massachusetts, USA
[119]Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
[120]Department of Medicine (Medical Genetics), University of Washington, Seattle, Washington, USA
[121]Department of Biostatistics, University of Washington, Seattle, Washington, USA
[122]Department of Genome Sciences, University of Washington, Seattle, Washington, USA
[123]Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, New York, USA
[124]Gertrude H. Sergievsky Center, Columbia University, New York, New York, USA

[125]Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, Florida, USA
[126]Department of Neuroscience, Mount Sinai School of Medicine, New York, New York, USA
[127]Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
[128]Department of Neurology, Columbia University, New York, New York, USA
[129]Uniformed Services University of the Health Sciences; The American Genome Center, Bethesda, USA
[130]Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Rouen, France
[131]Inserm, Bordeaux Population Health Research Center, UMR 1219, Univ. Bordeaux, ISPED, CIC 1401-EC, Univ Bordeaux, Bordeaux, France
[132]CHU de Bordeaux, Pole santé publique, Bordeaux, France
[133]Univ Lille Inserm 1171, CHU Clinical and Research Memory Research Centre (CMRR) of Distalz, Lille, France.
[134]Université de Paris, EA 4468, APHP, Hôpital Broca, Paris, France
[135]University Bordeaux, Inserm, Bordeaux Population Health Research Center, France
[136]Department of Neurology, Bordeaux University Hospital, Bordeaux, France
[137]Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland
[138]Neuroscience Center Zurich, University of Zurich and ETH Zurich, Switzerland
[139]Zurich Center for Integrative Human Physiology, University of Zurich, Switzerland
[140]Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland
[141]Department of Geriatric Psychiatry, University Hospital of Psychiatry Zürich, Zürich, Switzerland
[142]Institute for Regenerative Medicine, University of Zürich, Switzerland
[143]Public Health Nutrition Unit, Institute of Nutrition and Food Technology, University of Chile, Chile
[144]Facultad de Ciencias para el Cuidado de la Salud, Universidad San Sebastián, Santiago, Chile
[145]Interuniversity Center for Healthy Aging RED21993, Santiago, Chile
[146]Biomedica Research Group, Centro de Estudios Clínicos, Santiago, Chile
[147]Departamento de Psiquiatría y Salud Mental, Campus Oriente, Facultad de Medicina, Universidad de Chile, Santiago, Chile
[148]Instituto Nacional de Geriatría, Santiago, Chile
[149]Clínica Alemana, Department of Neurology and Psychiatry, Santiago, Chile
[150]Geroscience Center for Brain Health and Metabolism, Santiago, Chile
[151]Latin American Institute for Brain Health (BrainLat), Universidad Adolfo Ibanez, Chile
[152]Memory and Neuropsychiatric Center (CMYN) Neurology Department, Hospital del Salvador y Facultad de Medicina, Universidad de Chile. Santiago, Chile
[153]Geriatrics Section Clinical Hospital University of Chile, Chile
[154]Neurology Service Hospital del Salvador, Santiago, Chile
[155]Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia
[156]Center of Excellence for Stress and Mental Health (CESAMH), VA San Diego Healthcare System, San Diego, CA, USA
[157]Center for Behavior Genetics of Aging, University of California San Diego, La Jolla, CA, USA
[158]VA San Diego Healthcare System, San Diego, CA, USA
[159]Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
[160]Center of Excellence for Stress and Mental Health, VA San Diego Healthcare System, San Diego, CA, USA
[161]Center for Behavior Genetics of Aging, University of California, San Diego, La Jolla, CA, USA
[162]5Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA
[163]Division of Aging, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
[164]Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
[165]Neurodegenerative Diseases Unit, Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Milan, Italy
[166]Dept. of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
[167]Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy
[168]Institute of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, Italy
[169]Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
[170]Interdisciplinary Department of Medicine, Geriatric Medicine and Memory Unit, University of Bari "A. Moro, Bari, Italy
[171]Centre for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, University of Perugia, Italy
[172]Department of Biomedical Sciences, University of Cagliari, Italy.
[173]Neurology, IRCCS San Gerardo dei Tintori, Monza and University of Milano-Bicocca, Italy
[174]Deaprtment of Clinical and Experimental Sciences, University of Brescia Italy
[175]Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia, Brescia, Italy
[176]Department of Neuroscience, Psychology, Drug Research and Child Health University of Florence, Italy
[177]IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy
[178]Past Director Dementia Unit University of Parma, Parma, Italy
[179]Department of Hematology and Stem Cell Transplant, Vito Fazzi Hospital, Lecce, Italy
[180]Department of Neuroscience "Rita Levi Montalcini", University of Torino, Torino, Italy
[181]Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy
[182]Neurology Unit, IRCCS Fondazione Policlinico Universitario A. Gemelli, Rome, Italy
[183]Laboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy
[184]Center for Alzheimer's and Related Dementias, NIH, Bethesda, MD, USA
[185]DataTecnica LLC, Washington, DC, USA
[186]Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, California, USA
[187]Pharmaceutical Sciences and Pharmacogenomics Graduate Program, University of California, San Francisco, California, USA
[188]Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA
[189]DataTecnica LLC, Washington, District of Columbia, USA
[190]Laboratory of Neurogenetics, NIH, Bethesda, MD, USA
[191]Niigata University, Brain Research Institute, Japan
[192]Research Center, National Center for Geriatrics and Gerontology, Japan

[193]UK Dementia Research Institute, Cardiff University, UK
[194]Institute of Neurology, Catholic University of the Sacred Heart, Rome, Italy
[195]Department of Neurology, Amitié Hospital, Bangui, Central African Republic
[196]Department of Neurology, Brazzaville University Hospital, Brazzaville, Republic of Congo
[197]Department of Radiology, Indiana University, Indianapolis, Indiana, USA
[198]Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
[199]Cluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD), University of Cologne, Cologne, Germany
[200]Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
[201]Department of Epidemiology, ErasmusMC, Rotterdam, The Netherlands
[202]Nuffield Department of Population Health Oxford University, Oxford, UK
[203]High Institute of Biotechnology, University of Monastir, Monastir, Tunisia
[204]Laboratory of Genetics, Immunology and Human Pathology, Faculty of Science of Tunis, University of Tunis El Manar, 2092 Tunis, Tunisia
[205]Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII, 28031 Madrid, Spain
[206]Centre for Precision Health, Edith Cowan University, Joondalup, Perth, Australia
[207]Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Perth, Australia
[208]Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, Australia
[209]Dept. of Public Health and Caring Sciences / Geriatrics, Uppsala University, Uppsala, Sweden
[210]Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada
[211]Tanz Centre for Research in Neurodegenerative Diseases, Departments of Medicine and Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada
[212]Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France
[213]Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
[214]Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, UK
[215]Research Center and Memory clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain
[216]Department of Biomedical Science, Chosun University, Gwangju, 61452, Republic of Korea
[217]Gwangju Alzheimer's & Related Dementia (GARD) Cohort Research Center, Chosun University, Gwangju, Republic of Korea
[218]Department of Neural Development and Disease, Korea Brain Research Institute, Daegu, 41062, Republic of Korea
[219]Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Medical Faculty, Cologne, Germany
[220]Department of Old Age Psychiatry and Cognitive Disorders, University Hospital Bonn, University of Bonn, Bonn, Germany
[221]German Center for Neurodegenerative Diseases (DZNE Bonn), Bonn, Germany
[222]Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA
[223]Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Disease (CECAD), University of Cologne, Cologne, Germany
[224]Well-aging Medicare Institute, Chosun University, Gwangju, 61452, Republic of Korea
[225]National Center for PTSD, Behavioral Sciences Division, VA Boston Healthcare System, Boston MA, USA
[226]Department of Psychiatry, Boston University Chobanian & Avedisian School of Medicine, Boston MA, USA
[227]Biomedical genetics/Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston MA, USA
[228]Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA

A polygenic score (PGS) for Alzheimer's disease (AD) was recently derived from data on genome-wide significant loci in European ancestry populations. We applied this PGS to populations in 17 European countries and observed a consistent association with AD risk, age at onset, and cerebrospinal fluid levels of AD biomarkers, independently of apolipoprotein E *(APOE)*. This PGS was also associated with the AD risk in many other populations of diverse ancestries. A cross-ancestry polygenic risk score (PRS) improved the association with AD risk in most of the multi-ancestry populations tested when the *APOE* region was included. Lastly, we found that the PGS/PRS, captured AD-specific information because the association weakened as the diagnosis was broadened. In conclusion, a simple PGS captures the AD-specific genetic information that is common to populations of different ancestries, but studies of more diverse populations are still needed for a better characterization of the AD genetics.

Over the last 15 years, genome-wide association studies (GWASs) have fostered the development of powerful approaches for characterizing disease processes and proposed diagnostic/prognostic tools such as polygenic scores (PGS)[1,2]. Given the high estimated heritability (60-80%, in twin studies) of Alzheimer's disease (AD)[3], a number of PGSs have been developed and their associations with AD risk or related phenotypes have been almost systematically reported[4,5,6,7,8,9,10]. However, comparisons across studies are complicated by marked differences in the populations analyzed, PGS-calculation methods, the summary statistics used, and the variants included[11]. Furthermore, most PGSs have been developed from studies of European-ancestry populations, and only a few studies have investigated PGS performance in populations of different ancestries[12,13,14,15].

In this manuscript, we first generated a PGS (PGS^{ALZ}) including the genome-wide significant, independent sentinel single nucleotide polymorphisms (SNPs) at the loci reported by Bellenguez et al.[16] excluding the *apolipoprotein E (APOE)* locus (n=83; see Supplementary Table 1 for the list of variants). We studied the associations between PGS^{ALZ} and AD risk or relevant endophenotypes in populations from 17 European countries. We next extended PGS^{ALZ} study to populations of diverse ancestries from Asia, Africa, Latin and North America. Finally, as already developed in other complex human diseases[17,18,19,20], we generated a cross-ancestry polygenic risk score (PRS) by integrating GWAS summary statistics from multiple populations to potentially improve PGS^{ALZ} predictive performance[21,22].

We first evaluated the association between PGS^{ALZ} and the risk of developing AD in case-control studies of European countries (see Supplementary Table 2 for population description and adjustments used per population; Supplementary Fig. 1-3 for PGS^{ALZ} distributions). PGS^{ALZ} was significantly associated with AD risk irrespective of *APOE* adjustment (Extended Fig. 1A and Supplementary Fig. 4). PGS^{ALZ} was similarly associated with AD risk in men and in women (Extended Fig. 1B and Supplementary Fig. 6) and with a younger age at onset (Extended Fig. 2). It is noteworthy that when the PGSs were adjusted for difference in PGS^{ALZ} distribution between the European populations, the association with AD remained similar (Supplementary Fig. 5).

As we did not identify any potential bias/heterogeneity when comparing PGS^{ALZ} in the European populations, we performed a combined analysis (mega-analysis) of our European datasets to assess the risk of developing AD within various PGS^{ALZ} strata: 0-2%, 2-5%, 10-20%, 20-40%, 60-80%, 80-90%, 90-95%, 95-98%, and 98-100% with the 40-60% PGS^{ALZ} stratum as the reference. We also generated a PGS that included both the sentinel AD GWAS loci and the two SNPs defining the ε2/ε3/ε4 *APOE* alleles. As expected, the risk of developing AD in the most extreme strata was particularly high when *APOE* was included (Fig. 1A). The association with PGS^{ALZ} was also significant in all strata analyzed, irrespective of *APOE* adjustment. In the 0-2% and 98-100% strata, PGS^{ALZ} was respectively associated with a more than 2-fold decrease in the AD risk and a more than 3-fold increase in the AD risk compared with the 40-60% stratum (Fig. 1A and Supplementary Table 3).

Since these results suggested an association for PGS^{ALZ} independently of *APOE*, we took advantage of our mega-analysis to determine how PGS^{ALZ} interacts with the *APOE* genotypes. We found a limited interaction between PGS^{ALZ} and the number *APOE* ε4 alleles on the risk of

developing AD ($p=3x10^{-4}$). We next stratified the mega-analysis into four *APOE* genotype groups (ε2ε2/ε2ε3, ε3ε3, ε2ε4/ε3ε4, and ε4ε4) and assessed the association between PGS^{ALZ} and the AD risk per quintile (0-20%, 20-40%, 60-80%, and 80-100%) for each subpopulation (reference: 40-60% stratum). PGS^{ALZ} was similarly associated with the AD risk in all the strata, even if a stronger association might be present among ε4ε4 carriers (Fig. 1B and Supplementary Table 4).

To determine whether PGS^{ALZ} is associated with AD pathophysiological processes, we analyzed GWAS data of CSF levels of Aβ42, tau and p-tau (n=13,051 individuals) as previously described[23]. PGS^{ALZ} was associated with a decrement in $A\beta_{42}$ levels and an increment in tau and p-tau levels whatever the adjustment on *APOE* (Fig. 2A,B and Supplementary Fig. 7). We also checked the available samples for a possible association between PGS^{ALZ} and $A\beta_{42}$ levels, tau and p-tau levels in quintiles (0-20%, 20-40%, 60-80%, and 80-100%); again, the 40-60% stratum served as a reference. As expected, PGS^{ALZ} was associated with the lowest and highest levels of p-tau and $A\beta_{42}$ in the 0-20% strata and, conversely, the highest and lowest levels of p-tau and $A\beta_{42}$ in the 80-100% stratum. (Fig. 2C and Supplementary Table 5).

We then extended the PGS^{ALZ} analyses to other European-ancestry populations (USA, Australia), populations from India, East Asia (China, Japan and Korea), North Africa (Tunisia), sub-Saharan Africa (Central African Republic/the Congo Republic), South America (Argentina, Brazil, Chile, and Colombia), and African-, Native- and Latino American ancestry populations from US studies (i.e. more than 75% African or Native American ancestry or self-reporting for Latino American populations; Extended Fig. 3A; supplementary Table 2 for population description). With the exception of the analyses for Korea and Japan (where respectively 72 and 74 SNPs were available), most PGSs were constructed from 78 to 85 SNPs (including APOE variants; Supplementary Table 1; Supplementary Fig. 8-10 for PGS^{ALZ} distributions). The strength of the *APOE* ε4-AD association differed by population, as previously described in the literature[24,25]. ORs ranged from 1.36 in sub-Saharan Africa to 5.46 in Maghreb (Extended Fig 3B).

As expected, the PGS^{ALZ} association with AD risk was strongest in European-ancestry populations in the USA or Australia. PGS^{ALZ} was also significantly associated with the AD risk in Maghreb, East Asia, Latino American and African American populations (Fig. 3A and Supplementary Fig. 11). Lastly, PGS^{ALZ} was not associated with AD risk in the sub-Saharan African and Indian populations; this might be related to the small sample size and corresponding lack of statistical power. PGS^{ALZ} was associated with a younger age at onset in most of the populations studied, with the notable exception of the Chinese and Korean populations (Extended Fig. 4). It is noteworthy that the APOE ε2/ε3/ε4 alleles influenced age at onset in the two latter populations (Supplementary Fig. 12).

To refine our analysis of these populations of diverse ancestries, we calculated the association between AD and PGS^{ALZ} quintile (0-20%, 20-40%, 60-80%, and 80-100%; reference: 40-60% stratum) and meta-analyzed them per ancestry (Fig. 3B and C, Supplementary Table 6 and Supplementary Table 7). The Indian, Maghreb and sub-Saharan African populations were excluded because of the small sample size. The strength of the association with PGS^{ALZ} decreased from the European American, East Asian, and Latino American populations to the African American population, in that order (Fig. 3B and supplementary Table 6). PGS^{ALZ} generated from European-ancestry population GWAS performed poorly in African-ancestry populations.

This latter observation was strengthened by analyzing the association between PGS^{ALZ} and AD risk as a function of the African American admixture. The strength of the association decreased as the percentage of African-ancestry increased and ultimately reached a level similar to that observed in our sub-Saharan African population: the association between PGS^{ALZ} and the AD risk in populations in whom more than 90% of the members were of African ancestry had an OR of 1.09 (95%CI 0.98-1.21, $P=1.4x10^{-1}$, adjusted on *APOE*). It is noteworthy that a similar pattern was observed in the Alzheimer Disease Sequencing Project (ADSP) Native American population: the strength of the association decreased as the Native American-

ancestry percentage increased from OR=1.21 (95%CI 1.12-1.32), $P=5.3x10^{-6}$ and OR=1.14 (95%CI 1.05-1.25), $P=2.6x10^{-3}$ to OR=1.12 (95%CI 1.02-1.24, $P=1.4x10^{-2}$ in the populations with more than 50%, 75% and 90% of individuals of Native American-ancestry, respectively; adjusted for *APOE*. A similar finding was seen in Chilean and Argentinian populations: the PGS^{ALZ} association weakened as the proportion of Native American ancestry rose[14].

We next checked whether we had fully captured the genetic information within the GWAS-defined loci in the non-European admixed populations. To this end, we developed a PGS (PGS^{ALZ+}) that included other SNPs associated with AD risk in non-European ancestry populations ($p<10^{-3}$) at the European-GWAS-defined loci (for details, see Online Methods). We used the summary statistics generated by Kunkle et al.[26], Lake et al.[27] and Shigemizu et al.[28], and added 30, 13 and 47 variants to the initial 83 PGS^{ALZ} variants for Latino American, East Asian and African American ancestries, respectively (Supplementary Table 8). We did not detect any increment in the strength of the PGS^{ALZ+} association with the AD risk or in PGS^{ALZ+} predictive performance, relative to PGS^{ALZ} (Supplementary Table 9).

By initially restricting our analyses to the genome-wide significant loci from European ancestry AD GWAS, we likely excluded genetic information associated with the risk of developing AD in these European populations and (especially) non-European multi-ancestry populations (for which ancestry-specific loci may exist). Furthermore, the effect sizes used to construct PGS^{ALZ} were extracted from European ancestry populations without taking account population differences. To deal with these various questions, we used the Bayesian polygenic modeling method PRS-CSx to build a cross-ancestry PRS (PRS)[20] which re-estimates variant effect sizes, by coupling diverse summary statistics with external ancestry-matched allele frequencies and local Linkage Disequilibrium structure, according to a sparseness parameter of the genetic architecture of AD. We used GWAS summary statistics generated from European (36,569 AD cases and 63,137 controls), African American (2,784 AD cases and 5,222 controls), Latino American (1,088 AD cases and 1,152 controls) and East Asian (3,962 AD cases and 4,074 controls) populations[26,27,28]. Polygenic Risk Scores (PRS), all adjusted for population structure, were generated in multi-ancestry populations from the Million Veteran Program (MVP; European, Latino American and African American ancestries), EPIDEMCA (Sub-Saharan Africa ancestry) and GARD studies (East Asian ancestry; Supplementary Fig. 13).
We assessed potential increment of PRS association with AD risk and predictive performance when the summary statistics of the European, African American, Latino American or East Asian populations were used independently (respectively, PRS^{EUR}, PRS^{AA}, PRS^{LA}, PRS^{EA}), or when they were combined (PRS^{COMB}) at multiple sparseness parameter (10^{-8}, 10^{-7}, 10^{-6}, 10^{-5}, 10^{-4}, 10^{-2} and 1). We initially excluded the APOE *region* to enable a comparison with PGS^{ALZ}. We did not observe any increases in the association with AD risk or predictive performance in the different multi-ancestry populations (Fig. 4, supplementary Figure 14, supplementary Table 10) with the exception of the Latin American MVP population. However, we cannot exclude the possibility that this improvement is due to overfitting. Next, we included the *APOE* region when generating the different PRSs. While no impact was observed in European-ancestry populations when comparing PRS^{EUR} and PRS^{COMB}), we detected a potential increment in both the strength of association with the AD risk and predictive performance when comparing PRS^{EUR} and PRS^{COMB} for all other populations, indicating that a cross-ancestry PRS is more effective than a PRS constructed solely from European summary statistics when the *APOE* region is included (whatever the global shrinkage parameter used; Fig. 5, supplementary Figure 14, supplementary Table 10).

Lastly, we leveraged the MVP data to determine how the association between PGS^{ALZ} or PRS^{COMB} (APOE region excluded) and the risk of AD changed in multi-ancestry populations as a function of diagnostic specificity. That is, we looked at how a PGS^{ALZ}/ PRS^{COMB} derived from AD case/control performed when the applied to cohorts when the diagnosis was broadened to dementia. In all the multi-ancestry population studied, the association between PGS^{ALZ}/

PRS^{COMB} and the AD risk weakened as the diagnosis became less specific (Fig. 6 and Supplementary Table 11).

Several major points can thus be highlighted from our work: (i) In European populations, the associations of PGS^{ALZ} with AD risk are potentially slightly impacted by the *APOE* genotype (suggesting two independent genetic entities for sporadic AD; *APOE* ε4-associated sporadic AD, and *APOE* ε4-unassociated sporadic AD as previously proposed[29]); (ii) this simple PGS^{ALZ} based on the largest GWAS from European populations and the resulting European GWAS-defined loci appears to be enough to detect AD genetic risk in most of the different ancestry populations. Our results thus suggest that most of the different ancestry populations are likely to be affected by shared pathophysiological processes driven in part by genetic risk factors; (iii) Conversely, it is observed in the genetics of complex traits[30] and other multifactorial diseases[17,31,32], a cross-ancestry PRS built with a Bayesian polygenic modelling method did not systematically outperform a simple PGS^{ALZ} (when the APOE locus is excluded). The small population size of GWAS for the different ancestry populations can significantly limit the power of the PRS-CSx approach, potentially explaining this observation. However, this may also indicate that a high proportion of AD genetic risk is already accounted for by the European ancestry GWAS-defined loci; (iv) When PRS includes the *APOE* region, this region appears to likely contain additional multi-ancestry genetic variability as already proposed[33,34,35,36]; (v) Finally, the PGS/PRS associations mainly captures genetic information related to AD as their association weakened as the diagnosis was broadened. This observation suggests that the quality of the clinical diagnosis can interfere with the measurement of the association between the PGS/PRS and the AD risk in a given population.

In conclusion, our study of diverse ancestry populations and AD highlights the importance of cross-ancestry analyses for characterizing the genetic complexities of this devastating disease and to evaluate AD risk assessments in various populations. However, the field of AD genetics is still limited by the size of GWASs in these diverse ancestry populations. In addition, it is likely that the different ancestry populations will differ strongly regarding rare/very rare variants associated with the AD risk. this could clearly impact PRSs association with AD risk and their predictive performances[37]. Both GWAS and sequencing studies of more diverse populations are thus needed for a better characterization of AD genetics.

Acknowledgments

We thank all the study participants, researchers, and staff for contributing to or collecting the data. We also thank the staff at the University of Lille's high-performance computing service. This work was funded by a grant (European Alzheimer&Dementia DNA BioBank, EADB) from the EU Joint Programme – Neurodegenerative Disease Research (JPND) and La Fondation Recherche Alzheimer. A.N. was funded by Fondation pour la Recherche Médicale (EQU202003010147) and La Fondation Recherche Alzheimer. UMR1167 is also funded by the Inserm, Institut Pasteur de Lille, Lille Métropole Communauté Urbaine, and the French government's LABEX DISTALZ program (development of innovative strategies for a transdisciplinary approach to Alzheimer's disease). Full consortium acknowledgements and funding are given in the Supplementary Note. We thank David Fraser for his help.

Author contributions

Project coordination: A.N., J-C.L; **data collection coordination**: A.N., Y.LG., J.G., M.D.G., S.V.D.L, E.N.D.M., J-F.D., H.A., V.E-P., A.Rui., K.H.L., T.I., A.Ram., M.L., J-C.L; **Data analyses**: A.N, R.She., B.G-B., Y.K., M.K., J.T., I.D.R., C.D., X.Z., Y.L.G. C.E.A-B., M.A.C.B., M.Gue., S.v.d.L., M.Gos., A.C., C.B., F.K; **EADB sample contribution**: I.d.R., A.C., S.V.D.L,., C.B., F.K., O.P., A.Sch., M.D., D.R., N.Sch., D.J., S.R-H., L.H., L.M.P., E.D., O.G., J.Wilt., S.H-H., S.Moe., T.T., N.Sca., J.C., F.M., J.P-T., M.J.B., P.P., R.S-V., V.Á. M.B., P.G-G., R.Pue., P.Mir., L.M.R., G.P-R., J.M.G-A., J.L.R., E.R-R., H.Soi., T.K., A.d.M., S.Meh., J.Hor., M.V., K.L.R., J.Q.T., Y.A.P., H.H. J.v.S., H.See., J.A.H.R.C., W.J.S., I.Ram., F.V., A.v.d.L. P.Sch., C.G., G.P., V.G., G.N., C.Duf., F.P., O.H., S.D., A.B., J-F.Del., E.G., J.P., D.G., B.Aro., P.Mec., V.S., L.P., A.Squ., L.T., B.Bor., B.N., P.C., D.S., I.Rai., A.Dan., J.Will., C.Mas., P.A., F.J., P.K., C.V.D., R.F-S., T.M., P.S-J., K.S., M.I., G.R., M.H., R.Sim., W.v.d.F., O.A., A.Rui., A.Ram., J-C.L., **Australian sample:** T.P., S.M.L.; **MVP sample contribution:** R.She., R.H., V.M., M.P., R.Z., M.Gaz., M.L.**; Salsa sample contribution:** M.Gos., C.S.B., B.F., Q.Y. S.S.; **ADSP sample contribution:** A.Gri., T.F., C.Cru., J.Hai., L.F., A.Des., E.W., R.M., M.P-V., B.K., A.Goa., G.D.S., B.V., L-S.W., Y.Y.L., C.Dalg., A.Say., H.L.L., J.S.Y., M.A.N., S.S.**; Africa sample contribution:** M.Gue., P-M.P., P.Mbe, B.Ban, N.B.S., L.Che., J-F.Dar.**; East Asia sample contribution:** Y.K., M.K., X.Z., H.C., N.Y.I., A.K.Y.F., F.C.F.I., A.M., N.H., K.O., S.N., J.G., V.E-P., K.H.L., T.I.**; South America sample contribution:** C.Dalm., C.E.A-B., M.A.C.B., N.O., T.J-C., C.Muc., C.Cue., L.Cam., P.Sol., D.G.P., S.K., L.I.B., J.O-R., A.G.C.M.,M.F.M., R.Par., G.A., L.A.d.M., M.A.R.S., B.d.M.V., M.T.G.C., B.Ang., S.G., M.V.C., R.A., P.O., A.Sla., C.G-B., C.A., P.F., E.N.d.M., L.M., H.A., A.Rui., A.Ram**; Core writing group**: A.N, B.G-B., J-C.L.

Competing Interests Statement

S.V.D.L is recipient of ABOARD funding, which is a public-private partnership funded by from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). C.C. has received research support from GSK and EISAI. The study's funders had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. C.C. is an advisory board member for Vivid Genomics and Circular Genomics and owns stocks. L.M.P. received personal fees from Biogen for consulting activities unrelated to the submitted work T.G. received consulting fees from AbbVie, Alector, Anavex, Biogen, Cogthera, Eli Lilly, Functional Neuromodulation, Grifols, Iqvia, Janssen, Noselab, Novo Nordisk, NuiCare, Orphanzyme, Roche Diagnostics, Roche Pharma, UCB, and Vivoryon; lecture fees from Biogen, Eisai, Grifols, Medical Tribune, Novo Nordisk, Roche Pharma, Schwabe, and Synlab; and has received grants to his institution from Biogen, Eisai, and Roche Diagnostics.

O.A.A. is a consultant to Cortechs and Precision Health AS, and has received speaker's honorarium from Lundbeck, Sunovion, Otsuka and Janssen.

Reference

1. Osterman, M. D., Kinzy, T. G. & Bailey, J. N. C. Polygenic Risk Scores. Curr Protoc 1, e126 (2021).
2. Kachuri, L. et al. Principles and methods for transferring polygenic risk scores across global populations. Nat Rev Genet 25, 8–25 (2024).
3. Gatz, M. et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63, 168–74 (2006).
4. Baker, E. & Escott-Price, V. Polygenic Risk Scores in Alzheimer's Disease: Current Applications and Future Directions. Front Digit Health 2, 14 (2020).
5. Desikan, R. S. et al. Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score. PLoS Med 14, e1002258 (2017).
6. Sabuncu, M. R. et al. The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. Cereb Cortex 22, 2653–61 (2012).
7. Mormino, E. C. et al. Polygenic risk of Alzheimer disease is associated with early- and late-life processes. Neurology 87, 481–8 (2016).
8. Xicota, L. et al. Association of APOE-Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults. Neurology 99, e462–e475 (2022).
9. Sleegers, K. et al. A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42. Alzheimers Dement 11, 1452–1460 (2015).
10. Hong, S. et al. Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Transl Psychiatry 10, 403 (2020).
11. Clark, K., Leung, Y. Y., Lee, W.-P., Voight, B. & Wang, L.-S. Polygenic Risk Scores in Alzheimer's Disease Genetics: Methodology, Applications, Inclusion, and Diversity. J Alzheimers Dis 89, 1–12 (2022).
12. Sariya, S. et al. Polygenic Risk Score for Alzheimer's Disease in Caribbean Hispanics. Ann Neurol 90, 366–376 (2021).
13. Jung, S.-H. et al. Transferability of Alzheimer Disease Polygenic Risk Score Across Populations and Its Association With Alzheimer Disease-Related Phenotypes. JAMA Netw Open 5, e2247162 (2022).
14. Dalmasso, M. C. et al. The first genome-wide association study in the Argentinian and Chilean populations identifies shared genetics with Europeans in Alzheimer's disease. Alzheimers Dement 20, 1298–1308 (2024).
15. Kikuchi, M. et al. Polygenic effects on the risk of Alzheimer's disease in the Japanese population. Alzheimers Res Ther 16, 45 (2024).
16. Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet 54, 412–436 (2022).
17. Koyama, S. et al. Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. Nat Genet 52, 1169–1177 (2020).
18. Lennon, N. J. et al. Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations. Nat Med 30, 480–487 (2024).
19. Keaton, J. M. et al. Genome-wide analysis in over 1 million individuals of European ancestry yields improved polygenic risk scores for blood pressure traits. Nat Genet 56, 778–791 (2024).
20. Ge, T. et al. Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations. Genome Med 14, 70 (2022).
21. Kachuri, L. et al. Principles and methods for transferring polygenic risk scores across global populations. Nat Rev Genet 25, 8–25 (2024).
22. Xiang, R. et al. Recent advances in polygenic scores: translation, equitability, methods and FAIR tools. Genome Med 16, 33 (2024).

23. Jansen, I. E. et al. Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers. Acta Neuropathol 144, 821–842 (2022).
24. Logue, M. W., Dasgupta, S. & Farrer, L. A. Genetics of Alzheimer's Disease in the African American Population. J Clin Med 12, (2023).
25. Miyashita, A., Kikuchi, M., Hara, N. & Ikeuchi, T. Genetics of Alzheimer's disease: an East Asian perspective. J Hum Genet 68, 115–124 (2023).
26. Kunkle, B. W. et al. Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. JAMA Neurol 78, 102–113 (2021).
27. Lake, J. et al. Multi-ancestry meta-analysis and fine-mapping in Alzheimer's disease. Mol Psychiatry 28, 3121–3132 (2023).
28. Shigemizu, D. et al. Ethnic and trans-ethnic genome-wide association studies identify new loci influencing Japanese Alzheimer's disease risk. Transl Psychiatry 11, 151 (2021).
29. Frisoni, G. B. et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci 23, 53–66 (2022).
30. Wang, Y. et al. Polygenic prediction across populations is influenced by ancestry, genetic architecture, and methodology. Cell genomics 3, 100408 (2023).
31. Smith, J. L. et al. Multi-Ancestry Polygenic Risk Score for Coronary Heart Disease Based on an Ancestrally Diverse Genome-Wide Association Study and Population-Specific Optimization. Circ Genom Precis Med 17, e004272 (2024).
32. Khan, A. et al. Genome-wide polygenic score to predict chronic kidney disease across ancestries. Nat Med 28, 1412–1420 (2022).
33. Naslavsky, M. S. et al. Global and local ancestry modulate APOE association with Alzheimer's neuropathology and cognitive outcomes in an admixed sample. Mol Psychiatry 27, 4800–4808 (2022).
34. Rajabli, F. et al. Ancestral origin of ApoE ε4 Alzheimer disease risk in Puerto Rican and African American populations. PLoS Genet 14, e1007791 (2018).
35. Bussies, P. L. et al. Use of local genetic ancestry to assess TOMM40-523' and risk for Alzheimer disease. Neurol Genet 6, e404 (2020).
36. Rajabli, F. et al. A locus at 19q13.31 significantly reduces the ApoE ε4 risk for Alzheimer's Disease in African Ancestry. PLoS Genet 18, e1009977 (2022).
37. Nagao, Y. Contribution of rare variants to heritability of a disease is much greater than conventionally estimated: modification of allele distribution model. J Hum Genet (2024) doi:10.1038/s10038-024-01281-2.

METHODS Online

Sample and variant quality controls

To ensure that the βs were completely independent of the summary statistics, all samples from ADGC, CHARGE and FinnGen GWASs were filtered out. In addition, Sample overlap was systematically assessed and there was no sample overlap between any of the non-US studies analyzed. Overlap between ADSP and MVP is likely to be negligible (no more than a few cases). For biomarker analysis, there is overlap of 460 samples between the American samples used in the biomarker analyses and the ADGC (which is included in the summary statistics we used to generate the β for the PGS^{ALZ}). However, this overlap is limited (less than 2.5%) and in addition, we only analyzed in these samples the association of PGS^{ALZ} with quantitative traits (p-tau, tau and Aβ42 CSF concentrations), limiting the risk of inflated results. After it met the conventional GWAS gold standard of sample quality control, each sample was included in the analyses[16]. If a discordance in the variant dose or covariate or a discordance between imputed and genotyped (if available) APOE status was observed, the sample was discarded. After the quality control, a demographic description of each study is shown in Supplementary Table 1[38]**.** Genotyped variants had to meet the gold standard GWAS variant quality control[16]. All the studies including genotyping data were imputed with the TOPmed reference panel[39,38]. If the variants were imputed, those with a Rsq below 0.3 were excluded. For whole-genome sequencing data, only variants passing the corresponding quality control were selected (see the supplementary information for the ADSP and China samples) (Supplementary Table 2). The global ancestry of each individual in the ADSP samples was determined with SNPweights v.2.1[40] using a set of ancestry-weighted variants computed on reference populations from the 1000 Genomes Project as in[41]. By applying a global ancestry percentage cutoff of >75%, the samples were assigned to the different ancestry populations. The ancestry of MVP participants was determined using the harmonized ancestry and race/ethnicity (HARE) method[42], which is similar to other genotype-based ancestry calling methods, except that concordance is checked between self-report and genetically inferred ancestry, and those with discrepant ancestry groups are not assigned a HARE category. Within-group PCs for ancestry were computed using FlashPCA2[43].

European mega-analysis methods

For the mega-analysis of European countries, we merged samples from five datasets: EADB-core, GERAD, EADI, Demgene, and Bonn. To adjust for the population structure, we computed principal components using the following procedure. From the list of 146,705 variants used in the principal component analysis of EADB-core[43], we extracted TOPMed imputed variants having an imputation quality ≥0.9 in each dataset; this resulted in 91,353 variants. Next, we set a genotype to "missing" if none of the genotype probabilities was higher than 0.8. Lastly, we merged all the datasets and removed variants for which the proportion of missing genotypes was above 0.02. Ultimately, 90,471 variants were fed into the principal component analysis (performed with FlashPCA2). The analyses were adjusted for the first 14 principal components, the genotyping chip, and the center.

PGS and PRS Computations

The equation used to calculate the PGSs and the coPRSs is as follow:

PGS^{ALZ}_{sample} or $coPRS_{sample} = \sum_{i=1}^{n}(\beta_i * genotype_{i,\ sample})$

where the PGS^{ALZ}/PRS is the sum per sample, of the product of the variant *i* effect size β_i, extracted from GWAS summary statistics, and the number of risk alleles of this variant *i*, either as a dosage or as a genotype.

The PGS^{ALZ} includes the 83 independent signals associated with AD[13], listed in Supplementary Table 1. We also calculated another PGS^{ALZ} combining the same 83 independent signals and the two SNPs encoding the APOE ε2 (rs7412) and APOE ε4 alleles (rs429358). The PGS^{APOE} includes only these two last SNPs. The stage I meta-analysis of EADB studies[13] without the UK Biobank samples, contained 39,106 clinically diagnosed AD cases versus 25,392 in the

stage II meta-analysis (including the ADGC, CHARGE and FinnGen data)[13]. To respect the independence between the samples and the GWAS summary statistics, in the PGS analyses, the European summary statistics used are from stage II or (for APOE variants only). In the PGS^{ALZ}/PRS analyses adjusted for difference in distribution between populations, the European more powerful summary statistics, *i.e.* stage I meta-analysis of EADB were preferred.

The PGS^{ALZ+} score was developed to include additional SNPs within the GWAS-defined loci to capture more genetic information in non-European-ancestry populations. Firstly, each locus's "start and end positions" (as specified in the GRCh38 assembly) were defined manually by looking at the regional plots and extracting (i) recombination rate peak positions, (ii) starts/ends of chromosomes, (iii) specific variant positions, or (iv) start/end positions of regions containing no variants. Next, insertions and deletions were excluded. Variants that were non ambiguous (i.e. A/T or C/G) and present in the 1000 Genomes Phase 3 data (1000GP3) and had an imputation quality above 0.3 in the EADB-core TOPMed imputations, were selected. To extract information of these variants in non-European-ancestry populations, we used the summary statistics generated by Lake et al., Shigemizu et al. and Kunkle et al. to represent Latino American, East Asian and African-American ancestries, respectively[27,28,26]. Since these summary statistics were based on the GRCh37 assembly, we lifted their positions and alleles in the GRCh38 assembly by using the Picard LiftoverVcf tool (v2.27.5) and restricting the process to variants with a minor allele frequency above 0.01. In order to remove variants in LD with the sentinel variant of each locus, we computed the LD between each sentinel variant and all other variants within the locus by using the 1000GP3 data restricted to samples representing European ancestries (EUR super-population), Latino American ancestries (AMR super-population plus IBS population), Japanese ancestries (JPT population) and African-American ancestries (AFR super-population). Since one of the sentinel variant (chr9:104903697:C:G) was not present in the 1000GP3 data, we replaced it with a proxy variant (chr9:104903754:G:GC, R^2=1 in the EUR super-population). In each set of summary statistics, we removed variants with R^2>0.1 in either the European summary statistics or the summary statistics for the corresponding ancestry. Lastly, we performed a clumping procedure on the remaining variants in each of the three ancestries by using plink v1.9, a p-value threshold of $1x10^{-3}$, a R^2 of 0.05 (as estimated in the corresponding 1000GP3 data samples, as described above), and a distance of 1Mb. For the PGS^{ALZ+}, this led us to select 30, 13 and 47 variants (in addition to the initial 85 PGS variants) for the Latino American, East Asian and African-American ancestries, respectively.

PRS-CSx[20,44] was, by the time of analysis, one of the most performing cross-ancestry PRS model method[45,46], without a validation dataset and using GWAS summary statistics. With a Bayesian high-dimensional regression framework model based on continuous shrinkage priors, the variant effect sizes were adaptively re-estimated, by coupling cross-ancestry GWAS summary statistics[13,26,27,28], and external ancestry-matched allele frequencies and local Linkage Disequilibrium structure, according to a global shrinkage parameter. This global shrinkage parameter provides the sparseness of the genetic architecture of AD, by avoiding over-shrinkage of true signals and by shrinking noisy signals. This sparseness was modeled for the values of 1, 10^{-2}, 10^{-4}, 10^{-5},10^{-6}, 10^{-7} and 10^{-8}, with the --meta option and the Strawderman–Berger prior default parameters (a = 1 and b = 0.5). The initial 1,297 432 variants present in the 1000 Genomes reference panel, were lifted over in GRCh38. Then, new ancestry-specific or joint-ancestry effect size estimates were obtained with PRS-CSx, leading to a maximal number of 1,292 532 variants in the joint-ancestry summary statistics, potentially included in the PRS computations. The coPRSs were computed per chromosome, with 1- joint-ancestry and 2- European ancestry and 3- ancestry-specific PRS-CSx-effect size estimates, using PLINK (v.2.0.a) software[47] and its --score option, then summed across all chromosomes.

Adjustment for difference in PGS^{ALZ}/PRS distribution across populations

To account for population structure, PRS_{raw} and PGS^{ALZ}_{raw} were adjusted for difference in distributions across populations[48]. The adjustment was performed with a selection of 84,035

variants, common to all studies, independent and well-imputed variants (R > 0.8). With this list of variants, FlashPCA2 projected the samples into the 1000G Phase 3 PC-space and calculated the projected PCs. For each study, the raw score was fit in a linear model, in controls, according to the 5 first projected PCs. This model was used to compute a predicted score in all the samples. The resulting adjusted score was the difference between the raw score and the predicted score.

Statistical analyses

The different scores (PGS or coPRS) were standardized in a standard normal distribution, using the mean and the standard deviation, calculated over all the samples. The associations between AD status and the different scores were tested in logistic regression, named according to the score and the covariates. The name "ALZinclAPOE" was attributed, if the score included variants in the APOE region (from 43Mb to 47Mb). The other covariates included age, sex, in addition to covariates specific to each study (Supplementary Table 2).

- Model PGS^{ALZ}: AD ~ PGS^{ALZ} + COV
- Model PGS^{ALZ}: AD ~ PGS^{ALZ} + COV + the count of APOE ε2 alleles + the count of APOE ε4 alleles (when adjusted on *APOE*)
- Model PRS: AD ~ PRS + COV
- Model PRS: AD ~ PRS + COV + the count of APOE ε2 alleles + the count of APOE ε4 alleles (when adjusted on *APOE*)
- Model $PRS^{ALZinclAPOE}$: AD ~ $PRS^{ALZinclAPOE}$ + COV

To estimate the proportion of phenotypic variance explained by the variance of the score, we computed the Nagelkerke's *Pseudo*-R^2_{Full} using the function Nagelkerke implemented in the package *rcompanion* in R[49,50]. A *Pseudo*-R^2_{Null} was computed including only the covariates. The adjusted *Pseudo*-R^2 is the difference between *Pseudo*-R^2_{Full} and the tied *Pseudo*-R^2_{Null}. This adjusted Pseudo-R^2 corresponds to the phenotypic variance explained by the genetic score only. The adjusted *Pseudo*-R^2 was also transformed into a liability scale, for ascertained case-control studies[51], using a prevalence value of 0.15.

We chose a prevalence of 15%, which we consider to be consistent for populations with an average age over 75. However, this prevalence is different in multi-ethnic populations of the same average age. Furthermore, the AD prevalence increases with age, so the genetic liability is not homogeneous across all age groups. AD heritability cannot be expressed as a single number because it depends on the ages of the cases and controls[52].

Quantile or percentile analyses

Depending on the value of the corresponding PGS^{ALZ}, the samples were classified into the reference group or into one of the test groups. In the mega-analysis, the reference group corresponded to the 40-60% percentile and was tested across different percentiles (0-2%, 2-5%, 5-10%, 10-20%, 20-40%, 60-80%, 80-90%, 95-98%, and 98-100%). In the *APOE*-stratified analysis and in the multi-ancestry analyses, the reference group was defined as the 40-60% percentile and was tested across different quintiles (0-20%, 20-40%, 60-80%, 80-100%). The multi ancestry analyses were performed for each population and then meta-analyzed per genetic ancestry using the inverse variance method, as implemented in METAL[53]. It should be noted that the Indian, North African and sub-Saharan African populations were excluded because of their small sample size.

- Model PGS^{ALZ}: AD ~ $Group_{0/1}(PGS^{ALZ})$ + COV
- Model PGS^{ALZ}: AD ~ $Group_{0/1}(PGS^{ALZ})$ + COV + number of APOE ε2 alleles + number of APOE ε4 alleles (when adjusted on *APOE*)
- Model $PGS^{ALZinclAPOE}$: AD ~ $Group_{0/1}(PGS^{ALZinclAPOE})$ + COV

Data Availability

1000GP3: http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/release/20190312_biallelic_SNV_and_INDEL/)
ADSP: https://dss.niagads.org/datasets/ng00067/

Code availability

The sets of scripts are available upon request.

Reference

38. Das, S. et al. Next-generation genotype imputation service and methods. Nat Genet 48, 1284–1287 (2016).
39. Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature 590, 290–299 (2021).
40. Chen, C.-Y. et al. Improved ancestry inference using weights from external reference panels. Bioinformatics 29, 1399–406 (2013).
41. Le Guen, Y. et al. Multiancestry analysis of the HLA locus in Alzheimer's and Parkinson's diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes. Proc Natl Acad Sci U S A 120, e2302720120 (2023).
42. Fang, H. et al. Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-wide Association Studies. Am J Hum Genet 105, 763–772 (2019).
43. Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: principal component analysis of Biobank-scale genotype datasets. Bioinformatics 33, 2776–2778 (2017).
44. Ruan, Y. et al. Improving polygenic prediction in ancestrally diverse populations. Nat Genet 54, 573–580 (2022).
45. Ma, Y. & Zhou, X. Genetic prediction of complex traits with polygenic scores: a statistical review. Trends Genet 37, 995–1011 (2021).
46. Kurniansyah, N. et al. Evaluating the use of blood pressure polygenic risk scores across race/ethnic background groups. Nat Commun 14, 3202 (2023).
47. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).
48. Hao, L. et al. Development of a clinical polygenic risk score assay and reporting workflow. Nat Med 28, 1006–1013 (2022).
49. Lee, S. H., Goddard, M. E., Wray, N. R. & Visscher, P. M. A better coefficient of determination for genetic profile analysis. Genet Epidemiol 36, 214–24 (2012).
50. Choi, S. W., Mak, T. S.-H. & O'Reilly, P. F. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc 15, 2759–2772 (2020).
51. Lee, S. H. & Wray, N. R. Novel genetic analysis for case-control genome-wide association studies: quantification of power and genomic prediction accuracy. PLoS One 8, e71494 (2013).
52. Baker, E. et al. What does heritability of Alzheimer's disease represent? PLoS One 18, e0281440 (2023).
53. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–1 (2010).

Figure 1: Associations between the various PGSs and the risk of developing AD, as a function of *APOE* status. **(A)** The risk of developing AD, by PGS^{ALZ} stratum (0-2%, 2-5%, 10-20%, 20-40%, 60-80%, 80-90%, 90-95%, 95-98%, and 98-100%). The 40-60% PGS^{ALZ} stratum was used as the reference. **(B)** Risk of developing AD, by PGS^{ALZ} stratum (0-20%, 20-40%, 60-80%, and 80-100%) and the *APOE* genotype (by grouping together the $\varepsilon2\varepsilon2/\varepsilon2\varepsilon3$, $\varepsilon3\varepsilon3$, $\varepsilon2\varepsilon4/\varepsilon3\varepsilon4$, $\varepsilon4\varepsilon4$ carriers). The 40-60% PGS^{ALZ} stratum was used as the reference.

Figure 2: Association of PGS^{ALZ} with the level of $A\beta_{42}$ and p-tau in the cerebrospinal fluid **(A)** across European-ancestry populations and **(B)** according to PGS^{ALZ} strata (0-20%, 20-40%, 60-80% and 80-100%). The 40-60% PGS^{ALZ} stratum was used as the reference. Ncases, number of cases; Ncontrols, number of controls, OR, Odds ratio per standard deviation. The lines in the Forest plots indicate the 95% confidence interval for the ORs. If HetP <0.05, random-effect is shown for the meta-analysis results.

Figure 3: Association of PGS^{ALZ} across multi-ancestry populations. **(A)** Association of PGS^{ALZ} with the risk of developing AD in multi-ancestry populations. European-ancestry meta-analysis includes MVP and Australia. African-American-ancestry (more than 75% AA ancestry) meta-analysis includes MVP and ADSP. East-Asia meta-analysis includes China, Korea and Japan. Latino-American ancestry (self-reporting) meta-analysis includes MVP and ADSP. South-America meta-analysis includes Argentina, Brazil, Chile and Colombia. **(B)** Risk of developing AD according to PGS^{ALZ} (adjusted or not for *APOE* or included *APOE* variants) strata (0-20%, 20-40%, 60-80% and 80-100%) in multi-ancestry populations. The 40-60% PGS^{ALZ} stratum was used as the reference in each population and results were meta-analyzed. European-ancestry meta-analysis includes MVP and Australia. African-American ancestry meta-analysis includes MVP and ADSP. East-Asia meta-analysis includes China, Korea and Japan. Latin-American ancestry meta-analysis includes MVP and ADSP. South-America meta-analysis includes Argentina, Brazil, Chile and Colombia.
Ncases, number of cases; Ncontrols, number of controls; OR, Odds ratio per standard deviation. The lines in the Forest plots indicate the 95% confidence interval for the ORs. If HetP <0.05, random effect is shown for the meta-analysis results. EUR, European; LA, Latino-American; AA, African American.

Figure 4: Comparison of the association of PGS^{ALZ} or PRS (excluding *APOE* region) with AD risk and the corresponding predictive values (adjusted Nagelkerke R^2 and Liability R^2). All PGS^{ALZ} and PRS were adjusted for difference in distribution between populations; OR, Odds ratio per standard deviation; PRS^{EUR} were generated by using only European ancestry summary statistics; PRS^{COMB} were generated by combining European, African American (AA), Latin-American (LA) and East Asian ancestry summary statistics. Sparseness parameter at 10^{-8}, 10^{-7}, 10^{-6}, 10^{-5}, 10^{-4}, 10^{-3}, 10^{-2} or 1.

Figure 5: Association of PRS (including *APOE* region) with AD risk and the corresponding predictive values (adjusted Nagelkerke R^2 and Liability R^2). All PGS^{ALZ} and PRS were adjusted for difference in distribution between populations; OR, Odds ratio per standard deviation; PRS^{EUR} were generated by using only European ancestry summary statistics; PRS^{COMB} were generated by combining European, African American (AA), Latin-American (LA) and East Asian ancestry summary statistics. Sparseness parameter at 10^{-8}, 10^{-7}, 10^{-6}, 10^{-5}, 10^{-4}, 10^{-3}, 10^{-2} or 1.

Figure 6: Association of PGS^{ALZ} or PRS^{COMB} (excluding the *APOE* region) with AD, AD and related dementia (ADRD) and dementia in MVP and the corresponding predictive values (adjusted Nagelkerke R^2 and Liability R^2). PGS^{ALZ} and PRS were adjusted for *APOE* and for difference in distribution between populations; OR, Odds ratio per standard deviation; PRS-CSx were generated by combining European (EUR), African American (AA) and Latin-American (LA) and East Asian ancestry summary statistics. Sparseness parameter at 10^{-8} and 10^{-6}.

Extended Figure 1: Association of PGS^{ALZ} with the risk of developing AD **(A)** in 17 European countries and **(B)** in Men and Women. Ncases, number of cases; Ncontrols, number of controls; OR, Odds ratio per Standard deviation. The lines in the Forest plots indicate the 95% confidence interval for the ORs.

Extended Figure 2: Associations between (A) PGS^{ALZ} or (B) PGS^{ALZ} adjusted for *APOE* and age at onset of AD in European countries. N_{cases}, the number of cases. Since HetP <0.05, the random effect is shown for the meta-analysis results.

Extended Figure 3: Distribution and association of *APOE* ε2/ε3/ε4 alleles with AD risk worldwide. **(A)** World map showing the populations analyzed. A color gradient indicates the strength of the association between *APOE* ε2/ε3/ε4 alleles and the risk of developing AD in different countries **(B)** frequencies of *APOE* ε2/ε3/ε4 alleles in case and controls as well association of *APOE* ε4 alleles with the risk of developing AD in different countries.

Extended Figure 4: Association between (A) PGS^{ALZ} or (B) PGS^{ALZ} (adjusted for *APOE*) and age at onset of AD in multi-ancestry populations. N_{cases}, number of cases. The African-American-ancestry meta-analysis (more than 75% of the population with African-American ancestry) included the MVP and ADSP datasets. The East Asia meta-analysis included datasets from China, Korea, and Japan. The Latin American (LA) ancestry (self-reporting) meta-analysis included the MMVP and ADSP datasets. The South America meta-analysis included the datasets from Argentina, Brazil, Chile, and Colombia. * not used in the meta-analysis.


A
30.0
10.0
3.0
1.0
0.3
OR
0-2%
2-5%
5-10%
10-20%
20-40%
60-80%
80-90%
90-95%
95-98%
98-100%
Percentiles
PGS
PGS^ALZ
PGS^ALZ (Adjusted on APOE)
PGS^ALZ (+ APOE variants)


B
APOE ε22/ε23
APOE ε33
APOE ε24/ε34
APOE ε44
3.0
2.0
1.0
0.5
OR
0-20%
20-40%
60-80%
80-100%
Percentiles
Percentiles
0-20%
20-40%
60-80%
80-100%

A

$A\beta_{42} - PGS^{ALZ}$ (Adjusted on APOE)

Europe : I^2 = 65.1 , HetP = 1.43e-03 ; Global : I^2 = 62.6 , HetP = 1.94e-03

Country	N	Beta	95% CI	P-value
Finland	226	-0.155	[-0.28;-0.04]	1.22e-02
Sweden	264	-0.066	[-0.18;0.05]	2.52e-01
The Netherlands	3,106	-0.120	[-0.15;-0.09]	1.22e-14
Germany 1	314	-0.041	[-0.13;0.05]	3.99e-01
Germany 2	75	0.027	[-0.22;0.27]	8.33e-01
Germany 3	145	-0.213	[-0.37;-0.05]	1.04e-02
Germany 4	112	0.095	[-0.09;0.28]	3.23e-01
Belgium	598	0.022	[-0.05;0.10]	5.59e-01
France 1	439	-0.031	[-0.12;0.06]	4.87e-01
France 2	135	0.070	[-0.10;0.24]	4.34e-01
Spain	408	-0.152	[-0.24;-0.06]	7.04e-04
Meta-analysis Europe (random effect)	**5,822**	**-0.065**	**[-0.12;-0.01]**	**1.22e-02**
European American	7,229	-0.074	[-0.10;-0.04]	6.56e-07
Meta-analysis (random effect)	**13,051**	**-0.069**	**[-0.11;-0.03]**	**5.56e-04**
Adjusted for status				**3.50e-03**



B

$pTau - PGS^{ALZ}$ (Adjusted on APOE)

Europe : I^2 = 0 , HetP = 8.87e-01 ; Global : I^2 = 0 , HetP = 8.89e-01

Country	N	Beta	95% CI	P-value
Finland	226	0.082	[-0.09;0.26]	3.56e-01
Sweden	264	0.104	[-0.01;0.22]	8.14e-02
The Netherlands	3,106	0.104	[0.07;0.14]	4.22e-10
Germany 1	314	0.017	[-0.09;0.12]	7.55e-01
Germany 2	75	0.020	[-0.25;0.29]	8.89e-01
Germany 3	145	0.052	[-0.12;0.23]	5.64e-01
Germany 4	112	-0.046	[-0.24;0.15]	6.44e-01
Belgium	598	0.085	[0.01;0.16]	3.54e-02
France 1	439	0.084	[-0.01;0.18]	7.84e-02
France 2	135	0.060	[-0.13;0.25]	5.38e-01
Spain	408	0.088	[-0.01;0.19]	8.77e-02
Meta-analysis Europe	**5,822**	**0.089**	**[0.06;0.11]**	**1.82e-12**
European American	7,229	0.114	[0.06;0.17]	2.02e-05
Meta-analysis	**13,051**	**0.094**	**[0.07;0.12]**	**2.50e-16**
Adjusted for status				**7.05e-07**



PGS^{ALZ} (Adjusted on APOE)

C



A

PGS^{ALZ} (Adjusted on APOE)

Country	Ncases	Ncontrols	OR	95% CI	P-value	HetIsq	HetPVal
European American MVP	4,561	84,587	1.42	[1.37-1.47]	1.73e-88		
Australia	544	1,190	1.42	[1.26-1.59]	3.71e-09		
Meta-analysis EUR Ancestry	**5,105**	**85,777**	**1.42**	**[1.37-1.47]**	**4.68e-96**	**0**	**9.72e-01**
Maghreb	58	187	1.40	[0.95-2.09]	9.15e-02		
Sub-Saharan Africa	85	1,091	1.11	[0.88-1.38]	3.76e-01		
African American MVP	713	19,405	1.23	[1.12-1.34]	5.38e-06		
African American ADSP	1,108	2,325	1.14	[1.05-1.23]	1.23e-03		
Meta-analysis AA Ancestry	**1,821**	**21,730**	**1.17**	**[1.11-1.24]**	**5.68e-08**	**40.1**	**1.97e-01**
US LA Ancestry MVP	375	7,166	1.32	[1.16-1.49]	1.47e-05		
US LA Ancestry ADSP	1,629	2,456	1.27	[1.19-1.36]	3.31e-12		
Colombia	254	241	1.23	[0.99-1.53]	5.84e-02		
Brazil	301	178	1.64	[1.32-2.06]	1.12e-05		
Argentina	417	601	1.31	[1.14-1.52]	2.54e-04		
Chile	122	252	1.70	[1.32-2.22]	5.96e-05		
Meta-analysis US LA Ancestry	**2,004**	**9,622**	**1.28**	**[1.21-1.36]**	**2.68e-16**	**0**	**6.19e-01**
Meta-analysis South America	**1,094**	**1,272**	**1.40**	**[1.27-1.55]**	**1.16e-11**	**52.6**	**9.66e-02**
Meta-analysis LA Ancestry	**3,098**	**10,894**	**1.31**	**[1.25-1.38]**	**7.50e-26**	**45.1**	**1.05e-01**
China	453	786	1.34	[1.18-1.53]	1.12e-05		
Japan	2,220	2,472	1.30	[1.21-1.38]	4.88e-15		
South Korea	1,119	1,172	1.34	[1.22-1.46]	3.01e-10		
Meta-analysis East Asia	**3,792**	**4,430**	**1.31**	**[1.25-1.38]**	**6.71e-28**	**0**	**8.21e-01**
India	105	1,500	0.98	[0.79-1.20]	8.13e-01		



B

PGS^{ALZ} (Adjusted on APOE)



C

PGS^{ALZ} (+APOE variants)




MVP EUR
MVP LA
MVP AA
South Korea
OR
2.00
1.50
1.00
Adj Nagelkerke R²
0.03
0.02
0.01
0.00
Liability R²
0.80
0.60
0.40
0.20
0.00
PGS^ALZ
10e^−08
10e^−07
10e^−06
10e^−05
10e^−04
10e^−02
1
Score
PRS^EUR
PRS^COMB


MVP EUR
MVP LA
MVP AA
South Korea
OR
2.50
2.00
1.50
1.00
Adj Nagelkerke R²
0.15
0.10
0.05
0.00
Liability R²
1.00
0.75
0.50
0.25
0.00
10e⁻⁰⁸ 10e⁻⁰⁷ 10e⁻⁰⁶ 10e⁻⁰⁵ 10e⁻⁰⁴ 10e⁻⁰² 1
Score
PRS^EUR
PRS^COMB


MVP EUR
MVP LA
MVP AA
OR
1.60
1.50
1.40
1.30
1.20
1.10
1.00
Adj Nagelkerke R²
0.03
0.02
0.01
0.00
Liability R²
0.60
0.40
0.20
0.00
PGS^ALZ
PRS^COMB
Phi= 10^−8
PRS^COMB
Phi= 10^−6
Disease
AD
ADRD
Dementia

A

PGS^{ALZ} (Adjusted on APOE)

I^2 = 17.8 , HetP = 2.54e-01

Country	Ncases	Ncontrols	OR	95% CI	P-value
Finland	1,118	1,770	1.41	[1.29-1.55]	2.32e-14
Norway	1,327	1,179	1.56	[1.42-1.71]	8.43e-20
Sweden	1,466	3,078	1.62	[1.51-1.75]	2.27e-37
Denmark	398	650	1.54	[1.32-1.79]	2.08e-08
United Kingdom	4,622	8,414	1.53	[1.46-1.61]	3.13e-73
The Netherlands	2,428	2,024	1.46	[1.35-1.57]	6.50e-24
Belgium	1,211	1,431	1.57	[1.42-1.74]	2.20e-17
Germany	2,190	3,141	1.52	[1.42-1.62]	9.18e-37
Austria/Switzerland	175	372	1.25	[1.03-1.52]	2.32e-02
Czech Republic	177	60	1.62	[1.10-2.45]	1.81e-02
Bulgaria/Greece	735	1,195	1.39	[1.20-1.61]	1.52e-05
Italy	2,973	1,251	1.51	[1.41-1.63]	2.15e-27
France	3,789	9,026	1.49	[1.43-1.56]	4.69e-73
Spain	3,103	1,615	1.62	[1.50-1.75]	2.91e-36
Portugal	80	74	1.30	[0.92-1.86]	1.42e-01
Meta-analysis	**25,792**	**35,280**	**1.52**	**[1.49-1.55]**	**4.93e-353**



B

PGS^{ALZ} (Adjusted on APOE)

Females : I^2 = 20.1 , HetP = 2.29e-01 ; Males : I^2 = 0 , HetP = 7.58e-01

Country	Gender	Ncases	Ncontrols	OR	95% CI	P-value
Finland	Females	716	914	1.36	[1.21-1.54]	2.57e-07
	Males	402	856	1.50	[1.31-1.72]	7.73e-09
Norway	Females	840	622	1.52	[1.34-1.73]	9.49e-11
	Males	487	557	1.61	[1.40-1.87]	1.12e-10
Sweden	Females	926	1,898	1.67	[1.52-1.83]	6.79e-26
	Males	540	1,180	1.54	[1.37-1.74]	5.46e-13
Denmark	Females	227	354	1.62	[1.33-1.98]	2.02e-06
	Males	171	296	1.42	[1.13-1.80]	2.59e-03
United Kingdom	Females	2,633	4,323	1.54	[1.45-1.65]	1.62e-40
	Males	1,989	4,091	1.52	[1.43-1.63]	1.98e-34
The Netherlands	Females	1,354	885	1.41	[1.26-1.57]	7.29e-10
	Males	1,074	1,139	1.49	[1.35-1.65]	1.59e-15
Belgium	Females	783	890	1.56	[1.36-1.79]	1.11e-10
	Males	428	541	1.58	[1.34-1.87]	5.37e-08
Germany	Females	1,347	1,755	1.55	[1.43-1.69]	7.79e-24
	Males	843	1,386	1.48	[1.34-1.64]	7.78e-15
Austria/Switzerland	Females	112	204	1.23	[0.96-1.57]	1.07e-01
	Males	63	168	1.32	[0.96-1.82]	9.27e-02
Czech Republic	Females	107	40	1.52	[0.93-2.59]	1.06e-01
	Males	70	20	1.83	[0.97-3.76]	7.55e-02
Bulgaria/Greece	Females	445	676	1.53	[1.26-1.87]	2.04e-05
	Males	290	519	1.20	[0.95-1.52]	1.31e-01
Italy	Females	2,015	715	1.51	[1.37-1.66]	3.40e-17
	Males	958	536	1.55	[1.37-1.76]	2.31e-12
France	Females	2,383	5,540	1.47	[1.39-1.55]	5.28e-44
	Males	1,406	3,486	1.54	[1.43-1.65]	3.74e-31
Spain	Females	2,076	1,027	1.60	[1.45-1.76]	3.04e-22
	Males	1,027	588	1.63	[1.43-1.87]	1.45e-12
Portugal	Females	60	56	1.10	[0.75-1.66]	6.31e-01
	Males	20	18	3.50	[1.34-12.77]	2.48e-02
Meta-analysis	**Females**	**16,024**	**19,899**	**1.51**	**[1.47-1.55]**	**3.49e-203**
	Males	**9,768**	**15,381**	**1.52**	**[1.48-1.57]**	**3.71e-149**



A

PGS^{ALZ}

I^2 = 62.4 , HetP = 1.42e-03

Country	Ncases	Beta	95% CI	P-value
Finland	1,118	-0.47	[-0.95;0.02]	5.99e-02
Norway	1,327	-0.29	[-0.77;0.19]	2.39e-01
Sweden	1,466	-1.45	[-2.01;-0.88]	5.30e-07
Denmark	398	-0.39	[-1.16;0.38]	3.19e-01
United Kingdom	4,622	-0.57	[-0.85;-0.29]	7.29e-05
The Netherlands	2,428	-0.05	[-0.47;0.36]	8.00e-01
Belgium	1,211	-0.63	[-0.93;-0.32]	5.95e-05
Germany	2,190	-0.92	[-1.30;-0.54]	2.79e-06
Austria/Switzerland	175	-0.46	[-1.35;0.42]	3.04e-01
Bulgaria/Greece	735	-0.13	[-0.74;0.48]	6.67e-01
Italy	2,973	-0.34	[-0.66;-0.02]	3.76e-02
France	3,789	-1.04	[-1.38;-0.69]	3.18e-09
Spain	3,103	-0.45	[-0.76;-0.14]	4.85e-03
Meta-analysis (random effect)	**25,535**	**-0.56**	**[-0.75;-0.37]**	**6.87e-09**



B

PGS^{ALZ} (Adjusted on APOE)

I^2 = 60.9 , HetP = 2.17e-03

Country	Ncases	Beta	95% CI	P-value
Finland	1,118	-0.33	[-0.81;0.15]	1.72e-01
Norway	1,327	-0.28	[-0.75;0.20]	2.57e-01
Sweden	1,466	-1.35	[-1.89;-0.82]	8.54e-07
Denmark	398	-0.40	[-1.16;0.35]	2.93e-01
United Kingdom	4,622	-0.53	[-0.81;-0.25]	2.01e-04
The Netherlands	2,428	-0.05	[-0.47;0.36]	8.01e-01
Belgium	1,211	-0.61	[-0.91;-0.31]	6.06e-05
Germany	2,190	-0.88	[-1.25;-0.50]	4.93e-06
Austria/Switzerland	175	-0.49	[-1.37;0.40]	2.81e-01
Bulgaria/Greece	735	-0.13	[-0.75;0.48]	6.66e-01
Italy	2,973	-0.32	[-0.64;-0.01]	4.62e-02
France	3,789	-1.01	[-1.35;-0.67]	5.83e-09
Spain	3,103	-0.42	[-0.73;-0.11]	7.28e-03
Meta-analysis (random effect)	**25,535**	**-0.54**	**[-0.72;-0.35]**	**1.27e-08**



A



B

Country	Cases			Controls			OR ε_4
	ε_4	ε_3	ε_2	ε_4	ε_3	ε_2	
Finland	0.42	0.56	0.02	0.16	0.79	0.05	3.85 [3.33-4.46]
Norway	0.43	0.54	0.03	0.17	0.76	0.08	4.23 [3.62-4.95]
Sweden	0.41	0.57	0.03	0.16	0.77	0.08	3.90 [3.47-4.39]
Denmark	0.34	0.60	0.07	0.15	0.76	0.09	3.51 [2.71-4.53]
United Kingdom	0.33	0.63	0.04	0.13	0.79	0.08	3.39 [3.14-3.67]
The Netherlands	0.42	0.55	0.03	0.19	0.73	0.07	2.67 [2.38-2.98]
Belgium	0.31	0.64	0.05	0.13	0.79	0.08	3.50 [2.92-4.20]
Germany	0.33	0.63	0.05	0.12	0.79	0.09	3.67 [3.28-4.11]
Austria/Switzerland	0.19	0.74	0.07	0.10	0.82	0.08	2.11 [1.43-3.10]
Czech Republic	0.32	0.66	0.02	0.11	0.82	0.07	4.94 [2.22-10.99]
Bulgaria/Greece	0.23	0.74	0.03	0.09	0.85	0.06	2.17 [1.63-2.89]
France	0.30	0.66	0.04	0.10	0.82	0.07	3.65 [3.37-3.94]
Italy	0.25	0.73	0.03	0.09	0.86	0.05	3.69 [3.13-4.36]
Spain	0.27	0.70	0.03	0.10	0.85	0.06	3.73 [3.21-4.33]
Portugal	0.30	0.66	0.04	0.18	0.77	0.05	2.20 [1.19-4.05]

Country	Cases			Controls			OR ε_4
	ε_4	ε_3	ε_2	ε_4	ε_3	ε_2	
European American	0.26	0.68	0.06	0.12	0.80	0.08	2.96 [2.78-3.15]
African American	0.36	0.57	0.07	0.20	0.70	0.11	2.59 [2.35-2.84]
US LA Ancestry	0.23	0.73	0.04	0.10	0.85	0.05	2.25 [2.02-2.52]
Maghreb	0.27	0.72	0.02	0.10	0.87	0.03	5.46 [2.50-11.94]
Sub-Saharan Africa	0.28	0.62	0.11	0.23	0.65	0.12	1.36 [0.91-2.03]
Colombia	0.31	0.66	0.03	0.14	0.81	0.05	2.85 [1.97-4.13]
Brazil	0.28	0.68	0.03	0.12	0.81	0.07	3.73 [2.44-5.69]
Argentina	0.27	0.70	0.03	0.11	0.84	0.05	2.40 [1.73-3.33]
Chile	0.29	0.70	0.01	0.10	0.86	0.04	3.64 [2.26-5.86]
China	0.21	0.72	0.07	0.08	0.83	0.09	3.26 [2.49-4.26]
Japan	0.31	0.67	0.02	0.09	0.87	0.05	4.83 [4.24-5.49]
South Korea	0.26	0.70	0.04	0.08	0.86	0.06	3.64 [3.02-4.38]
India	0.17	0.79	0.04	0.11	0.84	0.05	1.61 [1.08-2.39]
Australia	0.40	0.57	0.03	0.14	0.77	0.09	4.16 [3.43-5.04]

A

PGS^{ALZ}

Country	Ncases	Beta	95% CI	P-value	I²	HetP
European American MVP	4,561	-0.42	[-0.66;-0.18]	5.98e-04		
Australia	544	-0.89	[-1.60;-0.19]	1.32e-02		
Meta-analysis EUR Ancestry	**5,105**	**-0.47**	**[-0.70;-0.24]**	**4.98e-05**	**34.5**	**2.16e-01**
African American MVP	713	-0.44	[-1.10;0.22]	1.88e-01		
African American ADSP	1,108	-0.75	[-1.26;-0.25]	3.56e-03		
*African American ADSP (90%)**	502	-0.30	[-1.02;0.42]	4.17e-01		
Meta-analysis AA Ancestry	**1,821**	**-0.64**	**[-1.04;-0.24]**	**1.81e-03**	**0.0**	**4.64e-01**
Native American (90%)	534	-0.97	[-1.79;-0.14]	2.18e-02		
US LA Ancestry MVP	375	-0.24	[-1.19;0.71]	6.19e-01		
US LA Ancestry ADSP	1,629	-0.60	[-1.02;-0.17]	5.87e-03		
Colombia	254	-0.12	[-1.24;1.00]	8.28e-01		
Brazil	301	-0.63	[-1.47;0.21]	1.43e-01		
Argentina	417	-0.30	[-0.97;0.36]	3.74e-01		
Chile	122	-1.89	[-3.75;-0.03]	4.64e-02		
Meta-analysis US LA Ancestry	**2,004**	**-0.54**	**[-0.93;-0.15]**	**6.51e-03**	**0.0**	**5.00e-01**
Meta-analysis South America	**1,094**	**-0.47**	**[-0.92;-0.01]**	**4.53e-02**	**1.5**	**3.85e-01**
Meta-analysis LA Ancestry	**3,098**	**-0.51**	**[-0.80;-0.21]**	**7.52e-04**	**0.0**	**6.15e-01**
China	453	0.08	[-0.49;0.66]	7.70e-01		
Japan	2,220	-0.29	[-0.53;-0.05]	1.60e-02		
South Korea	1,119	0.11	[-0.31;0.53]	6.02e-01		
Meta-analysis East Asia	**3,792**	**-0.16**	**[-0.35;0.03]**	**1.03e-01**	**43.0**	**1.73e-01**
India	105	-0.33	[-2.05;1.39]	7.03e-01		



B

PGS^{ALZ} (Adjusted on APOE)

Country	Ncases	Beta	95% CI	P-value	I²	HetP
European American MVP	4,561	-0.39	[-0.63;-0.15]	1.40e-03		
Australia	544	-0.91	[-1.61;-0.20]	1.16e-02		
Meta-analysis EUR Ancestry	**5,105**	**-0.44**	**[-0.67;-0.22]**	**1.22e-04**	**46.8**	**1.70e-01**
African American MVP	713	-0.47	[-1.13;0.18]	1.55e-01		
African American ADSP	1,108	-0.63	[-1.11;-0.14]	1.18e-02		
*African American ADSP (90%)**	502	-0.28	[-0.98;0.42]	4.29e-01		
Meta-analysis AA Ancestry	**1,821**	**-0.57**	**[-0.96;-0.18]**	**4.09e-03**	**0.0**	**7.12e-01**
Native American (90%)	534	-0.89	[-1.72;-0.06]	3.62e-02		
US LA Ancestry MVP	375	-0.21	[-1.15;0.73]	6.62e-01		
US LA Ancestry ADSP	1,629	-0.58	[-1.00;-0.17]	5.83e-03		
Colombia	254	-0.12	[-1.25;1.01]	8.34e-01		
Brazil	301	-0.68	[-1.50;0.15]	1.10e-01		
Argentina	417	-0.29	[-0.96;0.38]	3.93e-01		
Chile	122	-1.82	[-3.68;0.03]	5.35e-02		
Meta-analysis US LA Ancestry	**2,004**	**-0.52**	**[-0.90;-0.14]**	**6.90e-03**	**0.0**	**4.73e-01**
Meta-analysis South America	**1,094**	**-0.48**	**[-0.93;-0.02]**	**4.11e-02**	**0.0**	**3.94e-01**
Meta-analysis LA Ancestry	**3,098**	**-0.50**	**[-0.79;-0.21]**	**7.17e-04**	**0.0**	**6.19e-01**
China	453	0.12	[-0.44;0.68]	6.74e-01		
Japan	2,220	-0.27	[-0.51;-0.04]	2.17e-02		
South Korea	1,119	0.11	[-0.30;0.52]	5.90e-01		
Meta-analysis East Asia	**3,792**	**-0.14**	**[-0.33;0.05]**	**1.38e-01**	**43.6**	**1.70e-01**
India	105	-0.28	[-2.05;1.48]	7.52e-01